25 lives in exchange for 369.000 euro in savings. Which government dares to defend such an approach?
The story of Victor illustrates that Belgian policy is not ready yet to provide for the multiple, expensive drugs for rare conditions that are in the pipeline. A broader debate about structural reforms, the use of more objective criteria, and increasing price transparency in the pharma sector are recommended.
